These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29032739)

  • 1. Live Leishmania tarentolae secreting HNP1 as an immunotherapeutic tool against Leishmania infection in BALB/c mice.
    Abdossamadi Z; Taheri T; Seyed N; Montakhab-Yeganeh H; Zahedifard F; Taslimi Y; Habibzadeh S; Gholami E; Gharibzadeh S; Rafati S
    Immunotherapy; 2017 Oct; 9(13):1089-1102. PubMed ID: 29032739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice.
    Abdossamadi Z; Seyed N; Zahedifard F; Taheri T; Taslimi Y; Montakhab-Yeganeh H; Badirzadeh A; Vasei M; Gharibzadeh S; Rafati S
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006123. PubMed ID: 29253854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmania tarentolae expressing CXCL-10 as an efficient immunotherapy approach against Leishmania major-infected BALB/c mice.
    Montakhab-Yeganeh H; Abdossamadi Z; Zahedifard F; Taslimi Y; Badirzadeh A; Saljoughian N; Taheri T; Taghikhani M; Rafati S
    Parasite Immunol; 2017 Oct; 39(10):. PubMed ID: 28833211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model.
    Katebi A; Gholami E; Taheri T; Zahedifard F; Habibzadeh S; Taslimi Y; Shokri F; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
    Mol Immunol; 2015 Oct; 67(2 Pt B):501-11. PubMed ID: 26298575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leishmania Parasite: the Impact of New Serum-Free Medium as an Alternative for Fetal Bovine Serum.
    Habibzadeh S; Doroud D; Taheri T; Seyed N; Rafati S
    Iran Biomed J; 2021 Sep; 25(5):349-58. PubMed ID: 34481426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F₁ cross-breed between susceptible BALB/c and resistant Swiss mice infected with Leishmania major exhibit an intermediate phenotype for lesion sizes and type 1 cytokines but show low level of total IgG antibodies.
    Kiige SG; Mutiso JM; Laban LT; Khayeka-Wandabwa C; Anjili CO; Ingonga J; Gicheru MM
    Scand J Immunol; 2014 May; 79(5):283-91. PubMed ID: 24498914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cationic Immune Stimulating Complexes Containing Soluble Leishmania Antigens: Preparation, Characterization and in Vivo Immune Response Evaluation.
    Mehravaran A; Jaafari MR; Jalali SA; Khamesipour A; Tafaghodi M; Hojatizade M; Abbasi A; Badiee A
    Iran J Immunol; 2015 Dec; 12(4):274-87. PubMed ID: 26714419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis.
    Breton M; Tremblay MJ; Ouellette M; Papadopoulou B
    Infect Immun; 2005 Oct; 73(10):6372-82. PubMed ID: 16177308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
    Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro leishmanicidal activity of antimicrobial peptide KDEL against Leishmania tarentolae.
    Cao L; Jiang W; Cao S; Zhao P; Liu J; Dong H; Guo Y; Liu Q; Gong P
    Acta Biochim Biophys Sin (Shanghai); 2019 Dec; 51(12):1286-1292. PubMed ID: 31761925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies.
    Bolhassani A; Taheri T; Taslimi Y; Zamanilui S; Zahedifard F; Seyed N; Torkashvand F; Vaziri B; Rafati S
    Exp Parasitol; 2011 Mar; 127(3):637-45. PubMed ID: 21187086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis.
    von Stebut E; Belkaid Y; Nguyen BV; Cushing M; Sacks DL; Udey MC
    Eur J Immunol; 2000 Dec; 30(12):3498-506. PubMed ID: 11093169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for antimicrobial peptide-based immunotherapy approaches in Leishmania control.
    Zahedifard F; Rafati S
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):461-469. PubMed ID: 29889579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
    Li J; Nolan TJ; Farrell JP
    Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical role of dendritic cells in determining the Th1/Th2 balance upon Leishmania major infection.
    Suzue K; Kobayashi S; Takeuchi T; Suzuki M; Koyasu S
    Int Immunol; 2008 Mar; 20(3):337-43. PubMed ID: 18195051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice.
    Von Stebut E; Ehrchen JM; Belkaid Y; Kostka SL; Molle K; Knop J; Sunderkotter C; Udey MC
    J Exp Med; 2003 Jul; 198(2):191-9. PubMed ID: 12860932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapeutic effects of chitin in comparison with chitosan against Leishmania major infection.
    Hoseini MH; Moradi M; Alimohammadian MH; Shahgoli VK; Darabi H; Rostami A
    Parasitol Int; 2016 Apr; 65(2):99-104. PubMed ID: 26518128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.
    Salehi M; Taheri T; Mohit E; Zahedifard F; Seyed N; Taslimi Y; Sattari M; Bolhassani A; Rafati S
    Immunotherapy; 2012 Nov; 4(11):1107-20. PubMed ID: 23194361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.
    Vilela Mde C; Gomes DC; Marques-da-Silva Ede A; Serafim TD; Afonso LC; Rezende SA
    Acta Trop; 2007; 104(2-3):133-9. PubMed ID: 17919443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.